Radiotherapy for patients suffering from malignant neoplasms has developed greatly during the past decades. Stereotactic radiosurgery (SRS) 
controlleed trials (RCT) and two meta-analyses only historical cohort studies are identified. Reported outcome measures are highly variable between studies. Studies with high methodological quality provide evidence, that whole-brain radiotherapy (WBRT) in addition to SRS and SRS in addition to WBRT is associated with improved local tumour control rates and neurological function. However, only in patients with single brain metastasis, RPA-class 1 (RPA = Recursive partitioning analysis) and certain primary tumour entities, this combination of SRS and WBRT is associated with superior survival compared to WBRT alone. Studies report no significant differences in adverse events between treatment groups. Methodologically less rigorous studies provide no conclusive evidence with regard to medical effectiveness and safety, comparing SRS to WBRT, neurosurgery (NS) or hypofractionated radiotherapy (HCSRT). The quality of life is not investigated in any of the studies. Within the searched databases a total of 320 economic publications are identified. Five publications are eligible for this report. The five re-ports have a quiet variable quality. Concerning the economic efficiency of alternative equipment, while assuming equal effectiveness, the calculations show, that economic efficiency depends to a large extend on the number of patients treated. In case the two alternative equipments are used solely for SRS, the Gamma Knife might be more cost-efficient. Otherwise an adapted linear accelerator is most likely to be beneficial because of its flexibility. One Health Technology Assessment (HTA) states, that the cost for a Gamma Knife and a dedicated linear accelerator are comparable, while an adapted version is cheaper. No reports concerning ethical, legal and social aspects are identified.
Discussion
Overall, quantity and quality of identified studies is limited. However, the identified studies indicate that the prognosis of patients with brain metastases is despite highly developed and modern treatment regimes still limited. Conclusive evidence with regard to the effectiveness of identified interventions is only available for the combined treatment of SRS and WBRT compared to SRS or WBRT alone. Furthermore, there is insufficient evidence to compare SRS with WBRT, NS or HCSRT. The efficiency of the different equipments depends to a great extent on the number and the indications of the patients treated. If dedicated systems are used to their full capacity, there is some evidence for superior cost-effectiveness. If more treatment flexibility is required, adapted systems seem to be advantageous. However, equal treatment effectiveness is a necessary assumption for these conclusions. The need for a treatment precision can influence the purchase decision. No reports concerning more recent therapeutic alternatives are currently available.
Conclusion
Combination of SRS and WBRT is associated with improved local tumour control and neurological function compared to SRS or WBRT alone. However, only for patients with single metastasis there is strong evidence that this results in improved survival compared to WBRT alone. Methodologically rigorous studies are warranted to investigate SRS compared to WBRT and NS and to investigate the quality of life in patients undergoing these treatment regimes. Concerning the type of equipment used, economic efficiency depends to a great extend on the capacity at which the system can be used. Dedicated systems might be favourable for a high number of patients, while lower patient counts probably favour adapted systems with their superior treatment flexibility. Using the equipment at its full capacity may result in a limited number of machines, what in turn may give rise to the question of an equal and easy access to this technology. Studies focusing on the comparative effectiveness and cost-effectiveness of different treatment options and their combinations, especially for the German setting, are warranted. 
Executive Summary 1. Introduction
Radiotherapy for patients suffering from malignant neoplasms has developed greatly during the past decades. Stereotactic radiosurgery (SRS) is one important radiotherapeutic option which is defined by a single and highly focussed application of radiation during a specified time interval. One of its important indications is the treatment of brain metastases. The equipment that is used for radiosurgery is quite expensive in terms of purchase and maintenance costs.
Research questions
The objective of this Health Technology Assessment (HTA) is to summarise the current literature concerning the treatment of brain metastasis and to compare SRS as a single or additional treatment option to alternative treatment options with regard to their medical effectiveness/efficacy, safety and cost-effectiveness as well as their ethical, social and legal implications. To investigate these objectives, the following research questions will be addressed. Medical research questions: 
Ethical research question
To what extent can the access to this technology be ensured for the German population? 
Methods

Results
Of 1,495 publications 15 medical studies meet the inclusion criteria. Overall study quality is limited and with the exception of two RCT and two meta-analyses only historical cohort studies are identified. Apart from the outcome survival, reporting of outcome measures is highly variable between studies. None of the identified studies investigates the quality of life of patients undergoing certain treatment regimes. Studies with high methodological quality provide evidence, that whole-brain radiation therapy (WBRT) in addition to SRS and SRS in addition to WBRT is associated with improved local tumour control rates and neurological function. Only in patients with single brain metastasis, RPA-class 1 and certain primary tumour entities, this combination of SRS and WBRT is associated with superior survival compared to WBRT alone. Studies report no significant differences in adverse events between treatment groups. Four additional retrospective cohort studies report improved local tumour control associated with SRS compared to neurosurgery (NS). This does not, however, result in improved survival of patients treated radiosurgically. Methodologically less rigorous studies provide no conclusive evidence with re-5/9 GMS Health Technology Assessment 2009, Vol. 5, ISSN 1861-8863 gard to medical effectiveness and safety, comparing SRS to WBRT, or hypofractionated stereotactic radiotherapy (HCSRT). Two studies which compared different radiosurgical systems reported no difference in effectiveness and safety between Gamma Knife and Linac-based systems (LINAC = Linear accelerator). Of the 320 economic publications that are identified within the searched databasis four are found to be eligible for this report. One more publication is identified through a manual search. The five reports consist of three original studies and two Canadian HTA. None of these studies is a complete health economic evaluation. The quality of the studies is quite variable. The only results that can be reported concern the economic efficiency of alternative equipment for the treatment. One study compares the cost of a Gamma Knife and an adapted linear accelerator within an Australian setting for different indications. The authors thereby assume equal effectiveness of the alternatives. The calculations show, that economic efficiency depends to a great extend on the number of patients treated. In case that the two alternative equipments are used solely for SRS the Gamma Knife might be more costefficient. In case the adapted linear accelerator can be used to treat other patients as well, it is most likely that it is also the cost-efficient alternative. One HTA states similar costs for a Gamma Knife and a dedicated linear accelerator, while an adapted version is cheaper. The decision for the hardware can be influenced by the need for a certain precision in the treatment near sensitive areas. No reports concerning newer alternatives such as the CyberKnife are identified. The same holds for ethical, legal and social aspects.
Discussion
Overall, quantity and quality of identified studies are limited. The identified studies indicate that the prognosis of patients with brain metastases is despite highly developed and modern treatment regimes still poor and that survival is limited. Considering the addressed research questions, conclusive evidence with regard to the effectiveness of identified interventions is only available for the combined treatment of SRS and WBRT compared to SRS or WBRT alone, respectively. Combined treatment is in both cases associated with improved local tumour control and neurological function. However, only in certain subgroups of patients, this results in improved survival compared to WBRT. Due to the availability of only less rigorous studies, there is only some evidence for superior local tumour control of SRS compared to NS. This improved tumour control does not results in gains in survival, however. On the other hand, there is insufficient evidence to directly compare SRS with WBRT, or HCSRT. It should be further noted, that none of the identified studies investigates the quality of life in patients undergoing presented interventions. Furthermore, two studies provide some evidence that there is no difference in effectiveness/efficacy and safety between Gamma Knife and Linac-based systems. The evaluation of newer and less invasive radiosurgery systems is currently not available, however. The efficiency of different equipments depends on the number and indications of the patients treated. One publication compares the costs for radiosurgery with a Gamma Knife and with a linear accelerator for different indications. Thereby the authors assume equal effectiveness for the alternatives, acknowledging that this is still to be confirmed. If dedicated systems can be used to their full capacity, it can be suggested, that these systems are more cost-efficient. If the system needs to be used for other indications in order to reach full capacity, it is very likely that adapted linear accelerators are advantageous in terms of economic efficiency. Overall costs are reported to be comparable for dedicated linear accelerators and Gamma Knife, while adapted systems seem to be cheaper. No reports concerning newer alternatives such as the CyberKnife are identified. Resulting from the advice of using the equipment at full capacity wherever possible, is the ethical problem of an equal and easy access to this technology for the whole population.
Conclusion
On the basis of identified evidence, it can be concluded that the combination of SRS and WBRT is associated with improved local tumour control and at least over the initial 24 months with improved neurological function compared to SRS or WBRT alone. However, only in patients with single metastasis there is strong evidence that this results in improved survival compared to WBRT alone. A direct comparison of SRS and WBRT as up front treatment in methodologically rigorous studies is currently not available. The choice of treatment regimen, SRS, WBRT or combined treatment therefore depends on outcome measures, considered relevant, and also on certain patient characteristics which are associated with improved outcome under specific treatments. Comparing SRS and NS, there is some evidence that SRS is associated with superior tumour control. It does not result in superior survival, however. Methodologically rigorous studies are therefore warranted to investigate SRS compared to WBRT or NS and to investigate the quality of life in patients undergoing different treatment regimes. Further, the evaluation of newer and less invasive radiosurgery systems is to be awaited. From the economic literature, conclusions can only be drawn referring to the type of equipment used. Economic efficiency depends to a great extent on the capacity at which the system can be utilized. A high number of patients gives rise to an advantage for dedicated systems. Lower patient counts favour adapted systems because of their possible flexibility. Studies concerning other alternatives such as the CyberKnife are desirable. Overall more studies, also concerning comparisons of different therapies or combinations of therapies and especially studies suited for the German health system are recommendable.
Kurzfassung 1. Wissenschaftlicher Hintergrund
Für die Therapie maligner Neubildungen stellt die Strahlentherapie wichtige Behandlungsmöglichkeiten dar, die sich in den vergangenen Jahrzehenten aufgrund von Fortschritten der bildgebenden Verfahren und der Computertechnik deutlich weiterentwickelt haben. Zu den Techniken der Strahlentherapie gehört u. a. auch die stereotaktische Radiochirurgie (SRS), die durch eine einmalige Applikation fokussierter hoher Strahlendosen in einem klar definierten Zeitraum gekennzeichnet ist. Von besonderer Bedeutung ist die SRS für die Behandlung von Hirnmetastasen. Die Systeme, die für eine radiochirurgische Behandlung von Hirnmetastasen eingesetzt werden, sind dabei sowohl in der Anschaffung als auch im Unterhalt kostenintensiv. 
Medizinische Forschungsfragen
Schlussfolgerungen
Auf Grundlage der zur Verfügung stehenden Daten ist festzustellen, dass die Kombination von SRS und WBRT bei vergleichbarer Therapiesicherheit sowohl gegenüber alleiniger SRS als auch gegenüber WBRT mit einer verbesserten lokalen Tumorkontrolle und zumindest mittelfristig auch mit einer verbesserten Funktionsfähigkeit einher-geht. Gemäß einer verbesserten Überlebenszeit profitie
